医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KIST: Overcoming the Current Limitations of Cancer Immunotherapy Through Immunogenic Clearance

2018年08月06日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Cancer immunotherapy harnessing the immune system to treat cancer is drawing a lot of attention of many medical staff and researchers because of unprecedented responses in the clinic. However, for most types of cancer, only a minor fraction of patients respond to immunotherapy. Also, immunotherapy is expensive, and the rising costs of other essential cancer treatments add more to the financial burden. Researchers at the Korean Institute of Science and Technology (KIST) have released a next generation immunotherapy that activates the body’s own immune cells to eradicate cancer cells.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180806005001/en/

Figure of cancer immunotherapy through immunogenic clearance (Graphic: Business Wire)

Figure of cancer immunotherapy through immunogenic clearance (Graphic: Business Wire)

Dr. In-San Kim of KIST and Dr. Seung-Yoon Park of Dongguk medical college successfully collaborated to develop a drug that maximizes anti-cancer immunity by effectively activating dendritic cells (phagocytes). This drug enhances the phagocytes‘ ability to effectively take up the cancer cells, and further activates T cells recognizing only the cancer cells due to the amplified immune response, thereby making it possible to selectively attack the cancer to be.

Using a ROCK inhibitor that inhibits the ‘Rho kinase (ROCK)’ signal, the researchers demonstrated that the cancer cell-phagocytic capacity of dendritic cells is enhanced. In addition, the activity of these phagocytes can further activate important anti-cancer immune cells (CD8+ T cells) and effectively remove cancer.

Furthermore, the researchers found that doxorubicin, an existing anti-cancer drug that can induce the immunogenic death of cancer cells, coadministered with ROCK inhibitor can maximize tumor-specific immunity through immunogenic clearance. In particular, such therapeutic strategy not only effectively removes the primary tumor, but also prevents tumor recurrence by eliciting durable anti-tumor immunity.

Dr. Kim stated, “We have established a new understanding of ‘Intrinsic cancer vaccination’, which treats cancer by activating the intrinsic immune system of the human body to recognize cancer cells as an enemy. Moreover, ROCK inhibitor has already been approved for clinical use, and the strategy of combining this drug and doxorubicin opens the way for patients to access cancer immunotherapy easily instead of expensive treatments. It is expected to be used as a next-generation cancer immunotherapy that can overcome the limitations of current cancer immunotherapy.”

This research was published in recent issue of Nature Communications.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180806005001/en/

CONTACT

KIST
Dr. In-San Kim, 82-2-958-5935
iskim14@kist.re.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Asensus Surgical Announces Shinmatsudo Central General Hospital in Japan to Initiate Senhance Robotic Surgical System
  • 武田薬品、ガンマ・デルタ・セラピューティクスの買収により固形がんに対する同種ガンマ・デルタT細胞療法の開発加速を目指す
  • Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
  • 武田薬品工業: 新市場区分「プライム市場」の選択申請および改訂コーポレートガバナンス・コードに基づくコーポレート・ガバナンスに関する報告書の提出、ならびにガバナンス関連規程文書の公表について
  • Frazier Healthcare Partners完成8.3亿美元的生命科学公共基金超额认购